Clinical Trials /

Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency

NCT00952016

Description:

To assess the efficacy of methotrexate in a genetically selected population of patients with advanced colorectal cancer, who have loss of a particular gene, MSH2. The efficacy of methotrexate will be evaluated by the proportion of cases that have a significant response to treatment (objective response rate).

Related Conditions:
  • Colorectal Carcinoma
Recruiting Status:

Terminated

Phase:

Phase 2

URL:

https://clinicaltrials.gov/show/NCT00952016

Trial Eligibility

Document

Title

  • Brief Title: Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency
  • Official Title: A Non-randomised Phase II Trial of Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency

Clinical Trial IDs

  • ORG STUDY ID: CCR3107
  • NCT ID: NCT00952016

Conditions

  • Advanced Colorectal Cancer

Interventions

DrugSynonymsArms
Methotrexate

Purpose

To assess the efficacy of methotrexate in a genetically selected population of patients with advanced colorectal cancer, who have loss of a particular gene, MSH2. The efficacy of methotrexate will be evaluated by the proportion of cases that have a significant response to treatment (objective response rate).

Detailed Description

      The study will involve treating 29 subjects with methotrexate given intravenously. All
      subjects will receive treatment; there is no control arm or randomisation. The subjects will
      be known to have deficiency of MSH2, or a mutation (genetic change) in MSH2 that stops it
      functioning normally. This can either be demonstrated by testing for loss of MSH2 protein in
      the tumour itself, or by the demonstration of a mutation in the MSH2 gene in the subject's
      blood.

Trial Arms

NameTypeDescriptionInterventions

Eligibility Criteria

        Inclusion Criteria:

          -  Confirmed diagnosis of metastatic or locally recurrent colorectal carcinoma

          -  Aged 18 years or older

          -  Paraffin embedded histological material available for analysis

          -  Either confirmed loss of expression of MSH2 on immunohistochemistry IHC or confirmed
             mutation in MSH2 on gene sequencing

          -  Life expectancy of > 3 months

        Exclusion Criteria:

          -  Previous treatment with methotrexate, either for malignant or non-malignant disease,
             except when methotrexate was given at low dose with other drugs to modify their
             effects

          -  Concomitant uncontrolled medical conditions

          -  Concomitant metastatic malignancy apart from non-melanotic skin cancers and carcinoma
             in situ of the uterine cervix in the last 10 years

          -  Any contraindication to treatment with methotrexate (as this will affect safety)
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Objective response rate, to include complete response and partial response, as defined radiologically using RECIST (Response, Evaluation Criteria in Solid Tumours) on imaging CT scans performed during treatment.
Time Frame:
Safety Issue:
Description:

Secondary Outcome Measures

Measure:Disease stabilisation rate; progression free survival; 1 year survival and median overall survival; Quality of Life assessment; toxicity assessment.
Time Frame:
Safety Issue:
Description:

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Terminated
Lead Sponsor:Royal Marsden NHS Foundation Trust

Trial Keywords

  • colorectal cancer
  • MSH2
  • metastatic

Last Updated

October 14, 2016